2025 | Half-year results

Matthias Schupp, CEO | Dirk Kirsten, CFO Basel, 19 August 2025





Agenda

  1. Opening remarks and highlights H1 2025

  2. Financial review

  3. Strategic direction: from head to toe

  4. Outlook FY 2025

  5. Upcoming corporate events

Matthias Schupp, CEO

Dirk Kirsten, CFO

Matthias Schupp, CEO

Matthias Schupp, CEO

3

Highlightes H1 2025

Matthias Schupp, CEO

4





Half-year 2025 Key highlights



Organic revenue growth

+15.3% CER

Total sales reached CHF 123.0 million,

including three months of sales from NeoOrtho in Brazil from May onwards

Organic growth exceeded expectations and the upper end of guidance range

NeoOrtho integration

On plan

NeoOrtho integration in Brazil on plan

Back-office consolidation and new production facility in Curitiba to be concluded early 2026

KeriMedical partnership

US entry

We secured the remaining 53% stake in KeriMedical in July

Preparation for the market launch of the flagship product TOUCH in the USA

Guidance FY 2025

14-16% CER

Following satisfying trend in H1, we raise our full-year organic sales guidance to 14-16%

Unchanged high-teens core EBITDA margin despite US tariffs headwind

1 Organic growth denotes the increase in sales at constant exchange rates (CER), excluding the impact of M&A (i.e. NeoOrtho). 5

Attention: This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Medartis Holding AG published this content on August 19, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 19, 2025 at 05:03 UTC.